Sareum Holdings plc

good afternoon and welcome to the salarium holdings plc final results investor presentation throughout this recorded presentation investors will be in listen only mode questions are encouraged and they can be submitted at any time using the q a type situated on the right hand corner of your screen simply type in your questions and press send The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll and I would now like to hand you over to Senior Associate Partner at ICR Concilium, Jessica Hodgson. Good afternoon to you.

Good afternoon, everyone. Thanks very much for joining. This is SARIM's final results for the year ended June 30th, 2024. We have today presenting Dr. Stephen Parker, SARIM's executive chairman, Dr. Tim Mitchell, chief operating officer and co-founder, and Dr. John Reeder, chief scientific officer and co-founder. I'll now hand the call over to Dr. Stephen Parker.

Thank you Jessica and good afternoon everybody. Thank you for joining the call for the final results for the year to June 2024. Before we begin, because it is my first opportunity to talk to you as the Executive Chairman, I'd just like to reflect on a couple of issues, one of which of course is the fact of that change and Tim Mitchell has stepped sideways to take up the newly formed role of Chief Operating Officer as a part-time role Tim's contribution to this company of course doesn't need me to go into detail about it's very I'm sure very obvious to all of you but I would like to take the opportunity to Thank you very much A couple of words on the drug. Obviously, TIK2 has developed very rapidly now, even in the time that we were going through the Phase 1 trial in Australia, to have become recognized not only as a viable drug, and genuine target but a very attractive and valuable one as well and there have been one or two deals already in the space to underline that but I do think it also means that the general view when we're out talking to companies around the circuit that the working assumption is that although there have not been any efficacy trials as such yet those trials will be successful and therefore the safety as ever with any drug is the key question As John will go into detail in a few moments, the data coming out of the phase one study fulfilled all of our hopes and aspirations for the drug. And as a result, we've taken the view not to carry out the very small scale 1B study, which was still a safety study, but carried out in a small number of patients. but to prepare the drug to move forward as rapidly as we can to phase two trials and we'll obviously be discussing that further on as we go into the slides finally a word on my philosophy in this sector plc plc and having a plan depending on the outcome of any particular decision node and point. And as a result, several of the things that you've read about in recent weeks have fallen into place as we prepare 1801, as I say, for Phase 2 studies. with that i'd like to move into the slides so next thank you uh this of course is the usual disclaimer um so please do take note of it uh we are discussing uh forward-looking statements of various stages uh and um and and you should treat those with the uh the the caution that uh that always goes with them next slide please so moving on then to the the overview you know all of this pretty well um but we are a clinical stage company now uh we have a portfolio which is based upon the the the uh the jack cell signaling family principally tick two jack one uh although the expertise that that we have in jack twos and threes has helped John in particular to avoid the pitfalls that some of our competitors have found themselves in. 1801 has completed the Phase 1 clinical trial in Australia very successfully and on the back of that we recently went out and carried out a subscription to raise further funds And we now include the tax credit coming back from Australia. We've recently raised £4.4 million to move forwards with our plans for getting the drug ready for phase two. Next slide, please. So this is what the company's pipeline is looking like at the moment. Obviously, the bulk of our efforts have been focused on 1801 for some time now. with the benefit that you've all read about 1802 targeting the cancer immunotherapy we're now in a position to start to move that forwards into preclinical and hopefully prepare for clinical studies the partner drug SRA 737 Thank you very much. Next slide please. So from the year, obviously the most exciting result of all was the completion of the phase one study. Tremendous set of data coming back from Australia. No deaths or serious adverse events associated with the drug. um which obviously is every is is the first thing you look for and all the reported adverse events which rule by the mild or moderate uh were pretty much spread between the the the drug groups and the placebo placebo groups so we do believe that we're in as strong a position as possible to move forwards towards phase two As I said just now, the recent funding that we received will allow us to move 1802 forwards and we'll look to see an acceleration activity very rapidly there. I already mentioned the 737 project. program the deal that was done uh is uh worth 290 million dollars um with with an as yet unnamed us biopharma company we are waiting to uh as i said to get permission uh to reveal names uh and indeed progress uh once it's been reported back to the the uh cr uk organizations In terms of the financials, a very brief snapshot here. Cash at the end of June was 1.5 million, which was up from 1.0 million a year before. The loss has not surprisingly gone up slightly to 3.4 million from 3.2. Clinical trials are always expensive. and we've refilled the coffers to allow us to move the drug forward and the drugs forward as rapidly as possible with a total of 4.4 million pounds next slide please and with that I'd like to pass the baton over to Dr John Reader to take us through the inhibitor programs particularly the results from 1801